IPO

Mankind Pharma Limited IPO

Mainboard

Pharmaceuticals

Listed On: May 9, 2023 at ₹ 1300.0(NSE)

₹ 14040 /13 Shares

Check Allotment

25 Apr, 2023

Open Date

27 Apr, 2023

Close Date

03 May, 2023

Allotment Date

09 May, 2023

Listing Date
Price Summary

Last Closing

2,170.70 (100.99%)

52 Week High

3,054.80

52 Week Low

2,115.10

Last Update

12-Dec-2025 3:30 PM
Mankind Pharma Limited IPO Issue Details
  • Issue Price ₹1026-1080 per equity share
  • Face Value ₹1 Per Equity Share
  • Issue Price 40,058,844 shares(aggregating up to ₹4,326.36 Cr Offer for Sale)
  • Listing at BSE, NSE
  • List Price 1300.0(NSE)
  • Listing Date 2023-05-09
  • Lead Manager Kotak Mahindra Capital Company
    Axis Capital Limited
    IIFL Securities Ltd
    Jefferies India Private Limited
    J.P. Morgan India Private Limited
  • Registrar KFin Technologies Limited
Mankind Pharma Limited IPO Details
  • Retail Portion 35% (Number of Retail Applications : 10,78,500 Approx),
    (Number of sHNI Applications : 10,270 Approx),
    (Number of bHNI Applications : 20,540 Approx)
Mankind Pharma Limited IPO Documents
DRHP
RHP
ANCHOR
Mankind Pharma Limited IPO Details


The IPO of Mankind Pharma Limited is priced at ₹1026-1080 per equity share, which has a face value of ₹1 Per Equity Share each, IPO bidding starts from Apr 25, 2023 and ends on Apr 27, 2023. The allotment for Mankind Pharma Limited IPO will be finalized on May 3, 2023. Mankind Pharma Limited IPO will be listed on BSE, NSE, with a tentative listing date fixed as May 9, 2023. The company shall list its equity shares on the BSE, NSE. KFin Technologies Limited is the registrar of the issue.

The book-running lead manager for the IPO is/are Kotak Mahindra Capital Company, Axis Capital Limited, IIFL Securities Ltd, Jefferies India Private Limited, J.P. Morgan India Private Limited.


The Mankind Pharma Limited IPO sets its price band at 1026-1080 for each share. A single application for Mankind Pharma Limited IPO must contain at least 13 shares.

Read More
Mankind Pharma Limited IPO Subscription Analysis And Details
Retail
0.92x
QIB
49.16x
NII
3.80x
bNII
4.99x
sNII
1.41x
Total
15.32x
As on QIB NII
bNII   sNII 		Retail Total
Shares Offered / Reserved 8,011,769 6,008,827
4,005,885    2,002,942 		14,020,596 28,041,192
Day 1 25-04-23 05:00 PM
0.08 x 0.33
0.37 x   0.25 x 		0.10 x 0.14 x
Day 2 26-04-23 05:00 PM
1.86 x 1.02
1.21 x   0.64 x 		0.25 x 0.87 x
Day 3 27-04-23 05:00 PM
49.16 x 3.80
4.99 x   1.41 x 		0.92 x 15.32 x
Total No of Applications
4,62,790
Mankind Pharma Limited Valuations
Earnings Per Share (EPS) ₹33.2/-
P/E Ratio 32.5
RoNW 27.7%
Net Asset Value (NAV) - As on 31.12.22 ₹178.38
Mankind Pharma Limited Company Financials
In Crs.
In Cr.
31-Dec-22 31-Mar-22 31-Mar-21 31-Mar-20
Assets 9,273.75 9,147.74 6,372.63 5,073.29
Revenue 6,777.82 7,977.58 6,385.38 5,975.65
Profit After Tax 1,015.98 1,452.96 1,293.03 1,056.15
About Mankind Pharma Limited Company

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.

The company has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among these.

The company has its presence in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.

Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market (IPM). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.

The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.

Read More
Mankind Pharma Limited - Promoter(s)

Ramesh Juneja

Rajeev Juneja

Sheetal Arora

Ramesh Juneja Family Trust

Rajeev Juneja Family Trust

Prem Sheetal Family Trust

Pre Issue Share Holding : 79.00%

Post Issue Share Holding : 76.50%

Mankind Pharma Limited IPO - Issue Objectives
1

All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.

Mankind Pharma Limited IPO - Anchor Investors

Mankind Pharma raises Rs 1,298 crore from anchor investors.

The marquee investors that participated in the offer included Canada Pension Plan, Government of Singapore, Monetary Authority of Singapore, Goldman Sachs, Fiam Group Trust, Blackrock Global Funds, Abu Dhabi Investment Authority, Nomura Funds, Morgan Stanley, and Neuberger Berman Emerging Markets Equity Fund.

Mankind Pharma Limited IPO - Peers Comparison
P/B Ratio P/E Ratio RoNW Revenue(in Cr.)
Mankind Pharma 6.05 32.5 27.7% 7,977
Sun Pharma 4.50 29.8 14.0% 38,654
Cipla Limited 3.36 27.8 13.2% 21,763
Zydus Lifesciences 3.14 25.1 14.7% 15,265
Torrent Pharma 8.87 43.5 18.3% 8,508
Alkem Lab 4.37 39.0 20.7% 10.634
J B Chemicals & Pharma 7.10 40.4 18.1% 2,424
Eris Lifesciences 4.16 21.4 23.4% 1,347